-
-
05/28/2025ASCO 2025
Efficacy and safety of LM-302 (anti-claudin 18.2 ADC) in combination with anti-PD-1 therapy for advanced gastric, gastroesophageal junction cancer and esophageal adenocarcinoma: Early-phase study results
-
-
-
05/29/2024ASCO 2024
A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer
-
-
-
2022-10-2634th EORTC-NCI-AACR Symposium
Preclinical activity for TPX-4589 (LM-302), an antibody-drug conjugate targeting tight junction protein CLDN18.2 in solid tumors, Wentao Huang, Yifan Li, Zhifang Liu, Laura Rodon, Stephanie Correia, Yuan Li, Runsheng Li
-
我们非常重视您的个人隐私，当您访问我们的网站时，请同意使用的所有cookie。有关个人数据处理的更多信息可访问《隐私条款》
